-+ 0.00%
-+ 0.00%
-+ 0.00%

*SAB BIO: Proceeds Primarily to Fund Continued Development of Clinical Stage Product Candidate, SAB-142 >SABS

Dow Jones·03/18/2026 03:09:00

Please log in to view news